Another fledgling biopharma company is planning to go public.
And several prominent life sciences hedge funds that previously invested in the company are hoping this IPO fares better than the majority of recent offerings.
CARGO Therapeutics, a company purporting to advance a next generation of CAR T-cell therapies for cancer, last week filed plans with regulators to list its shares.
